Weight-loss surgery gets easier to access, obesity drugs harder

rss · YLE 2026-11-17T09:33:48Z en
New recommendations also emphasise treating people with obesity with respect, rather than blaming them for their weight. Ozempic is one of the popular semaglutide drugs available. Image: Kristiina Lehto / YleThe Finnish Medical Society Duodecim has published updated Current Care Guidelines (Käypä hoito) for obesity, setting out how doctors should assess and treat the condition. The recommendations aim to make it harder to obtain obesity medication through brief online consultations and improve access to bariatric surgery. Obesity remains a common problem in Finland, with one in three women and one in four men having a body mass index (BMI) above the obesity threshold. The use of weight-loss medication has also increased. According to benefits agency Kela, more than 100,000 people used obesity medication last year. The updated recommendations introduce four key changes to how patients are assessed and treated.1. Understanding the reasons behind eating habitsKirsi Pietiläinen, Professor of Clinical Metabolism and Chief Physician, says the central message of the new Current Care Guidelines for obesity is that patients should be treated with respect and never blamed for their weight. Pietiläinen chaired the expert group responsible for drawing up the recommendations. The updated guidelines call for a comprehensive assessment of each patient's circumstances, taking into account their health, life situation, lifestyle and personal wishes. Rather than simply advising patients on what to eat, healthcare professionals should seek to understand the reasons behind their eating habits."This is moving further and further away from the 1990s model, where a plate model of eating was shown and advice was given to eat this way. That is not the core of obesity treatment, but the core is understanding the person," says Chief Physician Pietiläinen. Pietiläinen emphasises that people cannot change their habits overnight, even when they understand the health benefits. Treatment should therefore identify the factors influencing a person's eating habits and find appropriate ways to address them.2. Stricter assessment before prescribing obesity medicationThe recommendation also addresses how doctors prescribe obesity medication, advising doctors against prescribing obesity drugs through quick, chat-based consultations. Under the recommendation, medication may be considered for patients with a BMI of at least 30, or 27 if they also have obesity-related health conditions. The guidelines do not favour specific products, but identify semaglutide and tirzepatide as the medications with the strongest scientific evidence. Semaglutide is the active ingredient in Ozempic, a diabetes medication widely used in Finland, as well as Wegovy, which is specifically intended to treat obesity. Mounjaro, another diabetes medication, contains tirzepatide.3. Easier access to bariatric surgeryThe criteria for bariatric surgery will also change. Patients will no longer need to lose 5 percent of their body weight before being referred for specialised medical care. Instead, they must first receive around six months of basic treatment through healthcare services. This may include lifestyle counselling and medication. Surgery can then be considered if these measures have not achieved sufficient weight loss or health benefits, Pietiläinen says. The BMI thresholds for surgery will also be lowered. A BMI of 35 will now be sufficient, compared with the previous threshold of 40. For patients with poorly controlled type 2 diabetes, the threshold will be 30-35. The recommendations also set an age limit of under 65 for surgery. Pietiläinen says the changes reflect updated international guidelines on bariatric surgery.4. Clearer guidance for healthcare professionals and patientsPietiläinen describes the new recommendations as more straightforward and practical than the previous ones. The updated guidelines also include printable information sheets for use by healthcare professionals during appointments. These can also be given to patients. However, the recommendations may need updating again in the near future as obesity medications continue to develop and new research emerges. There is still relatively little evidence on the long-term use and effectiveness of these medications, particularly as they have only been available for around a decade.

Knowledge Graph

Entities
Highlight